Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 p...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/2/133 |
id |
doaj-52191f18891c48e392688c5183a91c07 |
---|---|
record_format |
Article |
spelling |
doaj-52191f18891c48e392688c5183a91c072021-02-07T00:04:07ZengMDPI AGVaccines2076-393X2021-02-01913313310.3390/vaccines9020133Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease PatientsClaudia Sommerer0Anita Schmitt1Angela Hückelhoven-Krauss2Thomas Giese3Thomas Bruckner4Lei Wang5Paul Schnitzler6Stefan Meuer7Martin Zeier8Michael Schmitt9Department of Nephrology, University Hospital Heidelberg, University of Heidelberg, 69117 Heidelberg, GermanyDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, GermanyDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, GermanyGerman Center for Infection Research DZIF, Heidelberg, GermanyInstitute of Medical Biometry and Informatics, University of Heidelberg, 69117 Heidelberg, GermanyDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, GermanyDepartment of Virology, University Hospital Heidelberg, University of Heidelberg, 69117 Heidelberg, GermanyGerman Center for Infection Research DZIF, Heidelberg, GermanyDepartment of Nephrology, University Hospital Heidelberg, University of Heidelberg, 69117 Heidelberg, GermanyDepartment of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, GermanyIntroduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8<sup>+</sup> T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8<sup>+</sup> T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.https://www.mdpi.com/2076-393X/9/2/133cytomegalovirus (CMV)CMV reactivationphosphoprotein 65 (pp65) peptide vaccinationspecific T cellsrenal transplantation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Sommerer Anita Schmitt Angela Hückelhoven-Krauss Thomas Giese Thomas Bruckner Lei Wang Paul Schnitzler Stefan Meuer Martin Zeier Michael Schmitt |
spellingShingle |
Claudia Sommerer Anita Schmitt Angela Hückelhoven-Krauss Thomas Giese Thomas Bruckner Lei Wang Paul Schnitzler Stefan Meuer Martin Zeier Michael Schmitt Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients Vaccines cytomegalovirus (CMV) CMV reactivation phosphoprotein 65 (pp65) peptide vaccination specific T cells renal transplantation |
author_facet |
Claudia Sommerer Anita Schmitt Angela Hückelhoven-Krauss Thomas Giese Thomas Bruckner Lei Wang Paul Schnitzler Stefan Meuer Martin Zeier Michael Schmitt |
author_sort |
Claudia Sommerer |
title |
Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients |
title_short |
Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients |
title_full |
Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients |
title_fullStr |
Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients |
title_full_unstemmed |
Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients |
title_sort |
peptide vaccination against cytomegalovirus induces specific t cell response in responses in cmv seronegative end-stage renal disease patients |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2021-02-01 |
description |
Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8<sup>+</sup> T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8<sup>+</sup> T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned. |
topic |
cytomegalovirus (CMV) CMV reactivation phosphoprotein 65 (pp65) peptide vaccination specific T cells renal transplantation |
url |
https://www.mdpi.com/2076-393X/9/2/133 |
work_keys_str_mv |
AT claudiasommerer peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT anitaschmitt peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT angelahuckelhovenkrauss peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT thomasgiese peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT thomasbruckner peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT leiwang peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT paulschnitzler peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT stefanmeuer peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT martinzeier peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients AT michaelschmitt peptidevaccinationagainstcytomegalovirusinducesspecifictcellresponseinresponsesincmvseronegativeendstagerenaldiseasepatients |
_version_ |
1724282009470107648 |